NHLBI ADMINISTRATIVE SUPPLEMENTS FOR MICROARRAY APPLICATIONS AND ANALYSES Release Date: October 9, 2001 NOTICE: NOT-HL-02-003 National Heart, Lung, and Blood Institute (http://www.nhlbi.nih.gov/index.htm) The National Heart, Lung, and Blood Institute (NHLBI) announces the availability of administrative supplements to NHLBI grantees to facilitate the development and application of microarray technology for hypothesis-driven research related to cardiovascular, pulmonary, hematological, and sleep disorders. The Administrative Supplement program will encourage and support microarray technology use for those investigators that need funds to purchase or fabricate arrays, purchase or develop analysis software, and/or to isolate appropriate tissues or cells for microarray application. In addition to generating new expression data, investigators can request funds to analyze array data generated by NHLBI-supported investigators, such as the Programs for Genomic Applications (PGAs, http://www.nhlbi.nih.gov/resources/pga/index.htm), to ask hypothesis-driven questions specifically related to their own research. In addition, the NHLBI wishes to improve access to cutting-edge microarray technology for its grantees via improved access to state-of-the-art array facilities. Accordingly, the NHLBI will issue a companion initiative, the NHLBI Shared Microarray Facilities Program (RFA-HL-02-007). NHLBI grantees have identified major barriers to applying high-throughput, genome-wide expression analysis to their research, including the lack of funds to purchase or fabricate microarrays, and access to sophisticated bioinformatics tools to evaluate primary microarray data. Thus, the NHLBI will support the introduction of microarray technology and application in ongoing NHLBI research programs. Examples of research areas appropriate for this Administrative Supplement program include, but are not limited to (1) determination of genome-wide expression patterns and monitoring of changes under normal and experimental/pathological conditions related to any cardiovascular, pulmonary, hematologic, or sleep disorder, (2) identification of novel genes or expressed sequence tags (ESTs) involved in normal function, and pathogenesis of diseases within NHLBI’s mission, (3) development or refinement of software tools to analyze gene expression data. In addition, investigators can request funds to analyze already existing expression array data generated by NHLBI-supported investigators, such as the Programs for Genomic Applications. Investigators currently supported by the following NHLBI funding mechanisms are eligible to apply: Research Project Grant (R01), MERIT award (R37), Program Project (P01), Specialized Center of Research (P50), Comprehensive Sickle Cell Center (P60), Cooperative Agreement (U01), and Clinical Cooperative Agreement (U10). A minimum of 2 years must be remaining on an NHLBI-funded grant at the time a supplement is awarded. The work proposed must be within the scope of the research originally recommended by peer review. Applicants can request one year of support for no more than $75,000 in total costs. NHLBI intends to commit up to $2,250,000 in FY 2002 to fund up to 30 supplements. This is a one-time announcement. However, the NHLBI may re- release it in future years, depending on the needs of the NHLBI scientific community, and the availability of funds. There will be two receipt dates for administrative supplements: February 15, 2002, and June 15, 2002. Up to 15 awards will be made for each receipt date, depending on the receipt of a sufficient number of qualified applications and the availability of funds. Anticipated award dates are June 1, 2002 for the first receipt date, and September 30, 2002 for the second. Requests must be received by the application receipt dates, late applications will not be accepted. Amended applications will not be accepted. To apply for an administrative supplement, send an original letter and two copies countersigned by the grantee institution’s authorized business official to Dr. Martha S. Lundberg at the address below. The letter (5 pages limit) must include: 1) an abstract of the proposed supplemental activity and how it is related to the parent grant, 2) a detailed description of the proposed activity, including technical and/or analytical expertise, resources available, methodology, and plans for quality control, 3) expected overall impact of the requested supplement on ongoing research, 4) possible results, plans for independent confirmation and followup studies, and plans for dissemination of results, 5) a justification of the budget request including any requested equipment, physical arrays, software tools, methodologies (array platform), plans for data analysis and interpretation (bioinformatics), and plans for data sharing, and 6) current contact information for the principal investigator, including mailing and e-mail address. Although these descriptions should be as concise as possible, sufficient detail must be provided to allow the NHLBI to determine the merit of the requested supplement. A separate attachment (not included in the 5-page limit) should contain the parent grant number, abstract and specific aims, along with the budget pages for the requested supplement (not exceeding $75,000 in total costs for the one year). The budget should be submitted in the identical format as was used for the parent grant’s last competing application. That is, if the parent grant budget was modular, submit a modular budget, or if the parent grant was categorical, submit a categorical budget. Acknowledgment of receipt of the supplement letter will be provided by email. If the applicant has not received a response within ten business days, please contact Dr. Martha S. Lundberg at the address below. Requests may include purchase of equipment, tools for array fabrication, ready-to-use arrays, analytical tools, or any array-associated supplies. They may also include support for personnel who may collaborate with the principal investigator on experimental design, array construction, or array analysis. There is no restriction on the type of gene profiling technology that the applicant may select. NHLBI will consider supplement requests from all eligible applicants. Requests will be evaluated according to the following criteria: o The proposed research falls within the scope of the parent grant and is a logical extension of the goals and objectives, but not sufficiently different to constitute new research or program expansion. A research plan redundant with any portion of the studies approved under the parent grant will not be supported under this supplement program. o The applicant"s proposal will provide the resources and expertise necessary to design, perform and interpret the experiments. o The adequacy of the applicant"s plans for quality control and bioinformatics support and evidence that the investigator understands the uses and limitations of the technology and can handle data analysis and interpretation. o Documentation and justification of the requested budget. o The potential impact on the field. Supplement requests will be reviewed by a committee of NHLBI extramural scientific staff and outside scientists with appropriate expertise in the relevant scientific areas. The applicant will be notified of the evaluation decision within 3 months following the submission date. Amended applications will not be accepted. Award decisions will be based upon the criteria provided above, availability of funds, and NHLBI programmatic priorities and balance across heart, lung, and blood disorders. Direct inquiries regarding programmatic issues to: Martha S. Lundberg, Ph.D. Division of Heart and Vascular Diseases National Heart, Lung and Blood Institute 6701 Rockledge Drive Rockledge II, Rm 9146, MSC 7940 Bethesda, MD 20892-7940 Telephone: (301) 435-0513 FAX: (301) 480-1335 Email: lundberm@nhlbi.nih.gov Greg Evans, Ph.D. Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room10152, MSC 7950 Bethesda, Maryland 20892-7950 Telephone: (301) 435-0055 FAX: (301) 480-0868 Email: evansg@nih.gov Sandra Colombini Hatch, M.D. Lung Biology and Disease Program Division of Lung Diseases National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Suite 10124, MSC 7952 Bethesda, MD 20892-7952 Phone: (301) 435-0222 FAX: (301) 480-3557 Email: hatchs@nhlbi.nih.gov Heidi Krause-Steinrauf, M.S. Division of Epidemiology and Clinical Applications National Heart, Lung and Blood Institute 6701 Rockledge Drive, Rm 8151 Rockledge II, Rm , MSC 7936 Bethesda, MD 20892-7936 Telephone: (301) 435-0399 FAX: (301) 480-3667 Email: krauseh@nhlbi.nih.gov Direct inquiries regarding fiscal matters to: Raymond L. Zimmerman Grants Operations Branch National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 7156, MSC 7926 Bethesda, MD 20892-7926 Telephone: (301) 435-0171 FAX: (301) 480-3310 Email: ZimmmermR@nhlbi.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices



NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.